For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  FOXO4-DRI
Longevitypreclinical

FOXO4-DRI

FOXO4 D-Retro-Inverso
Longevity
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Longevity
Evidence grade
D
PubMed records
18
Female-tagged
1
Sex-analysis
0
CAS
—
D
Evidence grade D, Preclinical / animal evidence only across 18 indexed studies. No human trial data. How grades work →
Female evidence: None
FOXO4-DRI: of 18 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

FOXO4-DRI is a synthetic peptide built as a D-retro-inverso sequence, an engineering approach that reverses the amino-acid order and uses D-form residues to resist enzymatic breakdown. This design gives it a research-friendly profile as a stable tool compound in cellular-senescence investigation.

In preclinical and in-vitro systems, FOXO4-DRI has been studied for its ability to interfere with the interaction between the transcription factor FOXO4 and the tumor-suppressor protein p53. Researchers examining senescent-cell biology have used it as a research material to probe how disrupting FOXO4-p53 binding relates to senolytic mechanisms and the signaling that distinguishes senescent cells in laboratory models.

What makes FOXO4-DRI a notable catalog entry is the specificity of the protein-protein interaction it targets, which has made it a recurring reference compound in senescence research. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women. Supplied for in-vitro and laboratory research only.

Summary

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction and selectively clear senescent cells (a 'senolytic'). All evidence is preclinical; there are no human trials and no female-specific data.

Evidence in women

Menstrual cycle
Unstudied
No studies examine menstrual cycle interactions.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal data.
Sex differences
Unstudied
Preclinical senolytic studies did not report sex-stratified outcomes.

Mechanism

A retro-inverso peptide that competitively disrupts the FOXO4–p53 interaction, releasing p53 to trigger apoptosis selectively in senescent cells.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)No established human dose; senolytic activity shown in preclinical models only.
Routesintravenous, intraperitoneal
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

insufficient human data to characterize

FOXO4-DRI reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for FOXO4-DRI

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from FOXO4-DRI's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is FOXO4-DRI?

FOXO4-DRI, also known as FOXO4 D-Retro-Inverso, is a research compound in our longevity category. FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction and selectively clear senescent cells (a 'senolytic').

Is FOXO4-DRI studied in women?

FOXO4-DRI: of 18 PubMed records, 1 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for FOXO4-DRI is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has FOXO4-DRI been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does FOXO4-DRI have, and why?

FOXO4-DRI carries evidence grade D. Preclinical / animal evidence only across 18 indexed studies. No human trial data.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for FOXO4-DRI?

No. A female-specific dose for FOXO4-DRI is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is FOXO4-DRI administered in research?

In the published literature, FOXO4-DRI is administered via intravenous, intraperitoneal. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for FOXO4-DRI?

Effects reported in the research literature include insufficient human data to characterize. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should FOXO4-DRI be stored and handled?

FOXO4-DRI sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy FOXO4-DRI for research?

For laboratory research use, FOXO4-DRI is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy FOXO4-DRI at Aurevena Research
Research-use supplier: FOXO4-DRI is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

42024235 · 29260442

Related peptides

DSIPC
DSIP: of 462 PubMed records, 75 are tagged as including female subjects and 4 carry a sex-analysis tag.
EpitalonE
Epitalon: of 212 PubMed records, 65 are tagged as including female subjects and 0 carry a sex-analysis tag.
GDF-11D
GDF-11: of 658 PubMed records, 112 are tagged as including female subjects and 0 carry a sex-analysis tag.
GlutathioneC
Glutathione: of 23,989 PubMed records, 5,187 are tagged as including female subjects and 33 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.